학술논문
SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls.
Document Type
Article
Author
Source
Subject
*SYSTEMIC lupus erythematosus
*SEROCONVERSION
*SARS-CoV-2
*IMMUNOGLOBULINS
*IMMUNOGLOBULIN A
*SEROPREVALENCE
*
*
*
*
*
Language
ISSN
0961-2033
Abstract
None of the 173 SLE patients in the cohort, including the nine SLE patients with either intra-pandemic SARS-CoV-2 antibodies and/or a positive RT-PCR (Supplementary Table 1) were hospitalized for SARS-CoV-2 infection. SARS-CoV-2 antibody isotypes in systemic lupus erythematosus patients prior to vaccination: associations with disease activity, antinuclear antibodies, and immunomodulatory drugs during the first year of the pandemic. None of six controls with at least one pre-pandemic antibody to SARS-CoV-2 had neutralizing antibodies, whereas 4/7 controls with at least one intra-pandemic SARS-CoV-2 antibody had neutralizing antibodies, three of which had IgG antibodies to RBD. [Extracted from the article]